Investigating the Impact of Financial Sponsorship in Dermatology Research

Main Article Content

Umayr Shaikh
Ayushya Ajmani
David Makaj
Payal Shah

Keywords

financial sponsorship, early-career researchers, quality of evidence, innovation, authorship, degree status, journals, NIH, NIAMS, public funding, private funding, collaboration, impact, dermatologic research

Abstract

Introduction: Financial sponsorship plays a crucial role in advancing dermatologic research, yet its impact on research quality and visibility is not well-defined. This study aims to evaluate the association between financial sponsorship and the quality of evidence, publication impact, and research collaboration in dermatology.


Methods: We analyzed 1,380 dermatology articles published from October 2013 to October 2023 in three leading journals. Data collection was conducted using REDCap. We assessed the proportion of sponsored studies and their impact in terms of citation frequency, author count, and journal impact factors. Statistical analyses were performed using t-tests, chi-squared tests, and regression analysis in STATA VSN 16.1.


Results: Sponsored articles comprised 48.2% of the total, with the National Institutes of Health (NIH) being the predominant funder. These articles showed significantly higher citation rates and more authors per article compared to non-sponsored ones. The mean journal impact factor was also higher for sponsored studies. Furthermore, sponsored studies were more likely to employ prospective study designs, indicative of higher evidence quality.


Discussion: Financial sponsorship significantly enhances the visibility and quality of evidence in dermatologic research. The findings underscore the need for increased advocacy for funding, particularly in clinical research within dermatology, to foster greater research collaborations and more impactful scientific discoveries.

References

1. Chiang BM, Gelfand JM, Margolis DJ, Abuabara K. Distribution of Early Career Research Funding by Specialty from the National Institute of Arthritis and Musculoskeletal and Skin Diseases. J Invest Dermatol. 2023;143(5):688-690.e2. doi:10.1016/j.jid.2023.01.032

2. Matos TR, Walsh S, Stratigos AJ, Trakatelli M. Funding opportunities in the EU framework programme for skin disease. J Eur Acad Dermatol Venereol. 2024;38(4):625-626. doi:10.1111/jdv.19838

3. Burns PB, Rohrich RJ, Chung KC. The levels of evidence and their role in evidence-based medicine. Plast Reconstr Surg. 2011;128(1):305-310. doi:10.1097/PRS.0b013e318219c171

4. Hammond JB, Armstrong VL, McMullen K, Bernard RW, Teven CM. Aesthetic Surgery Research Funding: Where Does It Come From and to Whom Does It Go?. Aesthet Surg J. 2021;41(12):1473-1480. doi:10.1093/asj/sjaa335

5. Fabbri A, Lai A, Grundy Q, Bero LA. The Influence of Industry Sponsorship on the Research Agenda: A Scoping Review. Am J Public Health. 2018;108(11):e9-e16. doi:10.2105/AJPH.2018.304677

6. Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev. 2017;2(2):MR000033. Published 2017 Feb 16. doi:10.1002/14651858.MR000033.pub3